Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
11.33
-0.16 (-1.39%)
Mar 5, 2026, 4:00 PM EST - Market closed
Crescent Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
| Revenue | 10.84 | - |
| Gross Profit | 10.84 | - |
| Selling, General & Admin | 25.39 | 12.63 |
| Research & Development | 138.09 | 56.14 |
| Operating Expenses | 163.48 | 68.76 |
| Operating Income | -152.63 | -68.76 |
| Interest Expense | -2.19 | -3.41 |
| Interest & Investment Income | 2.88 | 0.7 |
| Pretax Income | -151.94 | -71.47 |
| Income Tax Expense | 2 | - |
| Net Income | -153.94 | -71.47 |
| Net Income to Common | -153.94 | -71.47 |
| Shares Outstanding (Basic) | 12 | 1 |
| Shares Outstanding (Diluted) | 12 | 1 |
| Shares Change (YoY) | 1465.00% | - |
| EPS (Basic) | -12.81 | -93.11 |
| EPS (Diluted) | -12.81 | -93.11 |
| Free Cash Flow | -72.45 | -25.08 |
| Free Cash Flow Per Share | -6.03 | -32.67 |
| Gross Margin | 100.00% | - |
| Operating Margin | -1407.53% | - |
| Profit Margin | -1419.61% | - |
| Free Cash Flow Margin | -668.12% | - |
| EBITDA | -152.55 | - |
| D&A For EBITDA | 0.08 | - |
| EBIT | -152.63 | -68.76 |
Source: S&P Capital IQ. Standard template.
Financial Sources.